Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Metastasis02:30

Metastasis

3.7K
3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The sleeping threat: targeting cancer dormancy to transform metastasis therapy.

Nature reviews. Cancer·2026
Same author

A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.

medRxiv : the preprint server for health sciences·2025
Same author

Midkine inhibits dormancy of disseminated melanoma cells.

bioRxiv : the preprint server for biology·2025
Same author

How much do we know about the metastatic process?

Clinical & experimental metastasis·2024
Same author

Oncogenic enhancers prime quiescent metastatic cells to escape NK immune surveillance by eliciting transcriptional memory.

Nature communications·2024
Same author

5-Azacytidine- and retinoic-acid-induced reprogramming of DCCs into dormancy suppresses metastasis via restored TGF-β-SMAD4 signaling.

Cell reports·2023

Related Experiment Video

Updated: Mar 19, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.3K

Dormancy programs as emerging antimetastasis therapeutic alternatives.

Maria Soledad Sosa1

  • 1Division of Hematology and Oncology; Department of Medicine; Icahn School Medicine at Mount Sinai; New York, NY USA; Tisch Cancer Institute, Mount Sinai School of Medicine; New York, NY USA.

Molecular & Cellular Oncology
|June 17, 2016
PubMed
Summary

The nuclear receptor subfamily 2, group F, member 1 (NR2F1) gene promotes tumor cell dormancy after surgery. Combining azacytidine with retinoids reactivates NR2F1, offering a strategy to prevent metastasis.

Keywords:
NR2F1dormancyhistonesminimal residual diseasepluripotencyquiescenceretinoids

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Experiment Videos

Last Updated: Mar 19, 2026

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

16.3K
An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Residual tumor cells can remain dormant after surgery, posing a risk for future metastasis.
  • The gene NR2F1 (nuclear receptor subfamily 2, group F, member 1) has been identified as a key regulator of tumor cell dormancy.

Purpose of the Study:

  • To investigate the role of NR2F1 in mediating tumor cell dormancy.
  • To explore therapeutic strategies for inducing tumor cell dormancy using NR2F1 reactivation.

Main Methods:

  • Analysis of NR2F1 gene expression in residual tumor cells.
  • Treatment of malignant cells with azacytidine and retinoids to assess NR2F1 pathway modulation.

Main Results:

  • NR2F1 was confirmed to mediate the postsurgical dormancy of both local residual and disseminated tumor cells.
  • The combination of azacytidine and retinoids effectively induced tumor cell dormancy by restoring the NR2F1-regulated gene program.

Conclusions:

  • NR2F1 plays a critical role in maintaining tumor cell dormancy post-surgery.
  • Targeting the NR2F1 pathway with azacytidine and retinoids presents a promising therapeutic approach to control minimal residual disease and prevent metastasis.